Phase-1 Trial: Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
RO7297089 is a bispecific tetravalent antibody targeting myeloma cells. In this MEDtalk, Fredrik Schjesvold, MD, PhD and the founder and leader of Oslo Myeloma Center at Oslo University Hospital, presents a phase I dose-escalation study, investigating the effect of RO7297089 in patients with RRMM. Results suggests a manageable safety but with lack of clinical efficacy with only two partial responses in 27 patients.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.